Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) was upgraded by equities researchers at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Friday.

Several other research analysts also recently weighed in on the stock. Zacks Investment Research upgraded shares of Anthera Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, June 13th. Jefferies Group LLC restated a “hold” rating and issued a $2.25 target price on shares of Anthera Pharmaceuticals in a research note on Monday, May 15th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $10.11.

Anthera Pharmaceuticals (NASDAQ ANTH) traded down 6.25% during midday trading on Friday, hitting $1.50. 440,349 shares of the stock traded hands. The company’s 50-day moving average is $1.40 and its 200-day moving average is $1.22. Anthera Pharmaceuticals has a one year low of $0.30 and a one year high of $3.42. The company’s market cap is $16.36 million.

Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($1.09) by $1.12. Equities research analysts expect that Anthera Pharmaceuticals will post ($3.68) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.watchlistnews.com/anthera-pharmaceuticals-inc-anth-stock-rating-upgraded-by-valuengine/1540210.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Sabby Management LLC boosted its stake in shares of Anthera Pharmaceuticals by 1,809.7% in the first quarter. Sabby Management LLC now owns 1,757,697 shares of the biopharmaceutical company’s stock valued at $748,000 after purchasing an additional 1,665,655 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Anthera Pharmaceuticals by 1,376.1% in the first quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 335,595 shares during the period. Finally, UBS Group AG boosted its stake in shares of Anthera Pharmaceuticals by 9.9% in the first quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 33,901 shares during the period. Institutional investors and hedge funds own 27.26% of the company’s stock.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Analyst Recommendations for Anthera Pharmaceuticals (NASDAQ:ANTH)

Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.